At meeting on human embryo editing, CRISPR pioneer says science is a long way from knowing if germline DNA can be safely ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Targeted CRISPR lipid nanoparticles eliminated 50% of tumors in mice with head and neck cancer.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...

近日,北京大学未来技术学院邬一谦研究团队在hLife上发表了题为"Boosting CAR-T cell therapy with CRISPR ...

Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...

Shares of CRISPR Therapeutics CRSP closed at $40.97 on Tuesday, close to their 52-week low of $36.52. This decline in CRSP ...

Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...

AWS’s framework will speed up the analysis of ElevateBio’s large protein datasets, hinting at promising drug candidates.